F-1/A: TC BioPharm Announces Offering of ADSs and Warrants to Fuel Clinical Trials

TC BioPharm is offering American Depositary Shares (ADSs) and warrants in a combined offering to raise capital for clinical trials and operating expenses.

Summary

• TC BioPharm (Holdings) PLC is offering 583,090 ADSs, each representing 200 ordinary shares, along with Series G warrants to purchase an equal number of ADSs.
• The offering also includes pre-funded warrants for certain purchasers who would otherwise exceed beneficial ownership limitations.
• The assumed public offering price is $3.43 per ADS and warrant, based on the closing price on August 7, 2024.
• Series G warrants have an exercise price of $2.71 per ADS and expire one year from the issuance date.
• Pre-funded warrants are offered at the ADS price less $0.001, with an exercise price of $0.001 per ADS.
• The offering is set to terminate on August 20, 2024, and the company estimates total expenses of approximately $0.2 million.
• The company intends to use the net proceeds to advance its preclinical and clinical pipeline, and for continuing operating expenses and working capital.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the capital raise is positive for funding future activities, the company's financial situation and dependence on future capital raises temper the outlook.

Positives

• The offering will provide capital to advance the company's clinical pipeline.
• The company has the ability to treat patients under the Specials regulatory framework.
• The company has a highly knowledgeable and experienced management team with extensive industry experience and expertise in the United States and in Europe.

Negatives

• The company has generated operating losses since inception and expects to continue to generate losses.
• The company, as well as its independent registered public accounting firm, in relation to its financial position, have expressed substantial doubt about its ability to continue as a going concern.
• The company has a lack of any approved products and its limited operating history may make it difficult for an investor to evaluate the success of its business to date and to assess its future viability.

Risks

• The company has generated operating losses since inception and expects to continue to generate losses.
• The company, as well as its independent registered public accounting firm, in relation to its financial position, have expressed substantial doubt about its ability to continue as a going concern.
• The company has a lack of any approved products and its limited operating history may make it difficult for an investor to evaluate the success of its business to date and to assess its future viability.
• GD-T cell therapies are a novel approach to treating cancers and infectious diseases, which have development risks and will require the company to obtain regulatory approvals for development, testing, commercialization, manufacturing and distribution.
• The company may not achieve all the required regulatory approvals or approvals may not be obtained as timely as needed.
• Because GD-T cell therapies are a novel approach, potential side effects, and long-term efficacy, regulatory approval will require considerable time for trials, data collection, regulatory submissions and funding for the process.
• Enrolling patients in clinical trials may be difficult for many reasons, including high screen failure, GD-T cell proliferation capacity, timing, proximity and availability of clinical sites, perceived risks, and publicity about the success or lack of success in the methods of treatment.
• Because GD-T cell therapies are novel, the company's research and development and clinical trial results may not support its products intended purposes and regulatory approval.
• The company is heavily dependent on the success of its lead product candidate (OmnImmune), and intend to seek breakthrough therapy designation for some or all of its other therapeutic candidates in due course.
• Market opportunities for certain of the company's product candidates may be limited to those patients who are ineligible for or have failed prior treatments.
• The company relies on many third parties for aspects of its product development and commercialization, such as raw material supply, clinical trials, obtaining approvals, aspects of manufacturing, development of additional product candidates and distribution.
• The company faces substantial competition: others may discover, develop and/or commercialize competing products before or more successfully than TCB.
• Even if the company is able to commercialize any product candidates, such drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies.
• Commercialized products may not be adopted by the medical profession.
• Because the company operates internationally, it is subject to a wide array of regulation of the United Kingdom, European Union and United States.
• Product liability claims are frequent in drug development of novel therapies and insurance is mandatory and expensive.
• Protecting the company's intellectual property is paramount in its ability to be able to commercialize its products and generate revenues and investment return for its stockholders.
• The company may not be able to obtain the intellectual property protection it seeks due to its cost, requirement to pursue it in many jurisdictions, challenges by others and patent office rejection.
• Obtaining and maintaining the company's patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies acting in multiple jurisdictions, and its patent protection could be reduced or eliminated for non-compliance with these requirements.
• As part of product development, the company may need to license aspects of its research and products from third parties or if its IP is challenged, it may have to seek license accommodation, any of which may be expensive, limited in scope, or unavailable.
• The company currently has a limited number of employees, and its future success depends on its ability to retain key executives and to attract, retain and motivate qualified personnel at all levels.
• The company will need to grow the size and capabilities of its organization, and it may experience difficulties in managing this growth including, but not limited to, operating as a public company and taking a therapeutic through to market approval and acceptance.
• The company expects to expand its development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, it may encounter difficulties in achieving and managing its growth, which could disrupt its operations.
• The company expects to require further funding for these expansions of activity.
• The company incurs substantial costs as a result of operating as a public company in the United States, and its management is required to devote substantial time to required SEC compliance and corporate governance practices.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect its business and its stock price.
• Certain of the company's existing stockholders, members of its board of directors and senior management maintain the ability to exercise significant control over it.
• The company's ADSs provide rights that are different from directly holding its ordinary shares.
• The outstanding Warrants do not have the rights of shareholders until exercised.
• The company's Warrants form a substantial part of its capitalization, and they have substantial protective provisions, which may limit its ability to raise capital.
• Future sales, or the possibility of future sales, of a substantial number of the company's ordinary shares, through the additional deposit of ordinary shares for ADSs and exercises of its Warrants, could adversely affect the price of its ADSs or Warrants in the market.
• As a foreign private issuer, the company, and its stockholders, have certain exceptions to disclosure regulation under United States federal securities regulation, and it will take certain NASDAQ governance exceptions.
• Shareholder rights and recourse will be governed by and ultimately determined by Scottish and United Kingdom law and judicial process, which in many ways are more limited than United States law and practice.
• Half of the company's directors and officers are not resident in the United States.
• Most of the company's assets are located in the United Kingdom.
• If the company fails to meet the requirements for continued listing on the Nasdaq Capital Market or Nasdaq, its ADSs could be delisted from trading, which would decrease the liquidity of its ADSs and its ability to raise additional capital.
• The price of the ADSs has been, and is likely to continue to be, highly volatile, which could result in substantial losses for purchases of ADSs in this offering.
• The company has broad discretion in the use of the net proceeds from this offering and any exercise of the Warrants and consequently may not use them effectively.
• If the company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired, which would adversely affect its business and its stock price.
• Purchasers who purchase the company's securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.
• Unstable market and economic factors could adversely affect the company's business, financial condition or results of operations.

Future Outlook

The company expects to be able to fund current operations to September 2024, through the period in which the Company will be preparing to initiate patient dosing in its upcoming clinical trials. The reaching of this value inflection point is reasonably expected to provide support for additional funding initiatives.

Industry Context

The announcement reflects a common strategy in the biopharmaceutical industry, where companies often raise capital through equity offerings to fund research and development, particularly clinical trials.

Comparison to Industry Standards

• Comparable companies in the biopharmaceutical sector, such as bluebird bio and 2seventybio, also utilize equity offerings to finance their operations.
• The terms of the warrants, including exercise price and expiration date, are generally consistent with industry standards for similar offerings.
• The use of pre-funded warrants to address beneficial ownership limitations is a relatively common practice in situations where investors may face such restrictions.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new shares and warrants.
• Employees: Continued funding for research and development activities.
• Customers: Advancement of potential new therapies.
• Suppliers: Ongoing business relationships.

Next Steps

• Complete the offering process and secure the funds.
• Advance preclinical and clinical pipeline programs.
• Continue operating and manage working capital.

Key Dates

Keywords

ADSs, Warrants, Offering, TC BioPharm, Clinical Trials, Capital Raise, Securities